Growth hormone
CJC-1295
Long-acting GHRH analog (with or without DAC)
CJC-1295 is a modified version of growth hormone-releasing hormone designed to last longer in the body. It was never approved by the FDA, and federal advisers have voted against allowing pharmacies to compound it.
Key facts
- Commonly discussed for: raising growth hormone and IGF-1.
- Evidence (C): The main human data are two small randomized, placebo-controlled trials in healthy adults (published 2006) that measured hormone levels, not health outcomes. No efficacy trials for a medical condition have been published.
- FDA status: Not recommended. On December 4, 2024 the PCAC voted 0-13 against adding CJC-1295 (free base) to the 503A Bulks List, agreeing with FDA, and the related salt forms were also rejected.
- Legitimate access: No clear legal route yet.
- Last reviewed: October 1, 2026.
Read the deep dives
Thinking about CJC-1295?
Add it to your stack, then bring the list to a licensed provider. They can tell you whether it fits your health picture and what the legitimate options are. Peptiblox never sells peptides or links to sellers. Check the legal status tracker for the latest FDA changes.
Open my stack →Sources
- Teichman et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab, 2006
- FDA: December 4, 2024 Pharmacy Compounding Advisory Committee summary minutes
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list)